載入中
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
前收盤價
US$1.98
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日內區間
目前US$1.98
52週區間
目前US$1.98
盤中時間採用ET。市場資料可能有所延遲。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日內區間
目前US$1.98
52週區間
目前US$1.98
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 45.1萬 USD | — | — | — |
| 銷貨成本 | — | 44.8萬 USD | — | 1000 USD | 1000 USD |
| 毛利 | — | 3000 USD | — | −1000 USD | −1000 USD |
| 研究與開發 | 2.8萬 USD | 9.8萬 USD | 3.1萬 USD | 3萬 USD | 3萬 USD |
| 銷售、一般及管理費用 | 112.9萬 USD | 204.6萬 USD | 73.4萬 USD | 85萬 USD | 100.1萬 USD |
| 營業費用 | 168.8萬 USD | 217.5萬 USD | 76.5萬 USD | 88萬 USD | 103.1萬 USD |
| 利息收入 | 6萬 USD | 3.4萬 USD | 4.1萬 USD | 3.6萬 USD | 8000 USD |
| 利息支出 | 7000 USD | 8.6萬 USD | 3999 USD | 1.1萬 USD | 2.1萬 USD |
| 折舊和攤銷 | — | 19.9萬 USD | 1000 USD | 1000 USD | 1000 USD |
| 營業利益 | −168.8萬 USD | −217.2萬 USD | −76.5萬 USD | −88萬 USD | −103.1萬 USD |
| 淨利 | −696.9萬 USD | −102.7萬 USD | −1782 USD | −134.8萬 USD | 43.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年3月25日 | 1:4 | — | — |
股票分割 | 2025年12月24日 | 1:4 | — | — |
股票分割 | 2017年2月10日 | 1:5 | — | — |
股票分割 | 2012年10月4日 | 1:10 | — | — |
已生效 2026年3月25日
1:4
已生效 2025年12月24日
1:4
已生效 2017年2月10日
1:5
已生效 2012年10月4日
1:10
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
